Sir, Despite a marked reduction in mortality and morbidity, even the most potent combined ARTs (cARTs) are currently inefficient at eradicating HIV-1 infection. 1 Early and prolonged cART after HIV-1 primary infection has recently been shown to be associated, in some individuals, with long-term viral control after treatment interruption. 2 -5 A Caucasian male patient in his mid-40s presented in July 2007 for post-exposure prophylaxis after unprotected anal intercourse 72 h earlier. The patient had tested HIV-negative in February 2007, had no symptoms and had an unremarkable physical examination. Post-exposure cART prophylaxis (tenofovir/emtricitabine/ lopinavir/ritonavir) was started despite late presentation. The day 0 blood work showed the presence of a Fiebig II HIV-1 infection with two combined positive ELISA tests [due to a positive p24 antigen (Ag) test], an indeterminate western blot and an HIV-1-RNA plasma viral load of 6.09 log copies/mL (Table 1) of subtype B, CCR5, wild-type virus. Probable infection was then linked to another unprotected sexual contact with a different HIV-infected partner 17 days earlier and cART was continued unchanged. Written consent was later obtained from the patient regarding the publication of these data.
At day 7 after cART initiation, HIV-RNA load had decreased by 1 log, while the p24 Ag and the Combo tests became negative (Table 1) . Within 1 month of cART, plasma HIV-RNA was below the lower limit of detection (LLD; 40 copies/mL). After initial positivity, tests for HIV-1 antibodies reverted, becoming fully negative after 3 years of cART (Table 1) . Repeated quantification confirmed sustainably undetectable levels of both circulating HIV-1-RNA (LLD 1 copy/mL) and proviral-DNA (LLD 10 copies/10 6 PBMCs). Rectal biopsy was performed after 3.5 years of cART and showed detectable, although unquantifiable, HIV-DNA.
In addition, the patient tested positive for the HLA-B*5701 allele and heterozygotic for the 32 bp deletion (D32) in the CCR5 gene. Normal responses against mitogenic and recall Ags were found.
Initial cART was modified several times during the first years of treatment for side effects, but HIV-1-RNA and -DNA were always controlled.
At the beginning of October 2012 the patient decided to interrupt cART (tenofovir/emtricitabine/maraviroc). As early as day 11 after cART interruption, the ELISA Genscreen test became positive without concomitant evidence of plasma HIV-RNA or p24 Ag, then a weak viral rebound was detected twice at day 21 (54 copies/mL) and at day 23 (95 copies/mL) of treatment cessation, without detection of HIV-DNA in the PBMCs. A decision was taken at this time to reintroduce cART and HIV-1 plasma undetectability was quickly regained, but HIV-1 antibodies remained positive for both ELISA tests with an incomplete western-blot test and undetectable levels of HIV-1-DNA in PBMCs ( Table 1) .
The patient was treated at 17 days of HIV-1 infection, before seroconversion, and he was HLA-B*5701 and D32 heterozygotic. On treatment, plasma HIV-RNA was ,1 copy/mL, cellular HIV-DNA remained below quantification for more than 5 years and HIV-1 antibodies were negative. cART interruption led to elicitation of antibodies after 11 days and to HIV-RNA detection after 21 days, confirmed at 23 days. The antibodies, but not the p24 Ag, remained positive 16 months after restarting cART and achieving a persistent plasma HIV-RNA ,20 copies/mL.
Seroreversion after early treatment of acute HIV-1 infection, although infrequent, has already been reported 6, 7 and was explained at least in part by the abrogation of antibody formation due to durable viral suppression. 7, 8 Indeed in our patient the initial Combo test positivity was due to the p24 Ag, which later became and remained negative under cART, while an HIV antibody response was never fully mounted, probably due to continuous viral suppression.
As indicated by others, 8 seroreversion does not mean viral eradication in patients treated early after primary infection. Similarly to another seroreversion case, 6 plasma HIV-1-RNA quickly rebounded in our patient after treatment interruption. Interestingly, the low level of circulating HIV-1 was able to induce specific anti-HIV antibody detection not reversible on cART. However, this report of seroreversion in an adult patient with sustained undetectable PBMC HIV-DNA supports recent data on early treatment limiting reservoir size, but indicates caution as to the distinction between maximal viral control, functional cure and the potential harm of treatment interruption. One can argue that treatment was reintroduced too early in this case with a low level of replication, ,400 copies/mL. Indeed, it has been shown that viral control can be maintained despite transitory viral replication 2 in about 15% of patients treated early, using the threshold of 400 copies/mL for viral control in the absence of treatment.
2 Actually, in this case, given the multiple favourable genetic, immunological and virological features, we chose the absence of detection of HIV replication as a more severe marker of functional cure and therefore treatment was reintroduced promptly when the virus became detectable. Thus, further studies are needed to better understand the significance of an undetectable cellular HIV reservoir and to characterize the patient profile required for HIV remission.
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